Abbott Post-Earnings: Street Stays Bullish, Peers Pull Ahead

Abbott Laboratories has printed its Q3 results today and the market's initial response is a modest pullback, with the stock off 1.5% to $102.45, even as the broader medical devices sector rallied sharply.

The peer divergence is the most striking feature of the day. MDT gained 2.0% and SYK jumped 2.2%, while BDX added 1.6%. That leaves Abbott as the session's clear laggard within its own correlated group, a reversal from the pre-earnings rally that had taken the stock to $104.89 just days ago. On the week, Abbott is essentially flat at minus 0.2%, while COO is up 8.3% and SYK has gained 7.7%. The gap tells a story about where post-print money is flowing, and it is not toward Abbott.

The positioning backdrop has shifted since the earnings preview published on October 18. Options markets were running the most defensive skew in months heading into the release, with the put/call ratio above two standard deviations above its 20-day average. That hedging has since partially unwound: the ratio has eased to 0.64, still a touch above its 20-day mean of 0.62 but no longer at the extreme. The event-protection trade appears to have been placed and settled. On the lending side, short interest is now 0.78% of the free float, down sharply from around 1.3% a month ago and down a further 1.9% on the week. Borrow costs have drifted back to 0.42% after spiking briefly in early October, and availability remains essentially unconstrained. There is no short-side pressure on this stock.

The Street's stance is constructive, though the gap between targets and the current price is widening. The consensus is Buy, with a mean target of $120.72, implying roughly 18% upside from here. TD Cowen reiterated its Buy at $135 as recently as October 16. Barclays initiated at Overweight with a $120 target on October 7, and Rothschild upgraded from Neutral to Buy with a $127 target on October 2. The bull case centres on Abbott's diversified revenue base, a raised full-year EPS guidance range of $5.45 to $5.60, and a second-half product cycle anchored by Libre, Volt 2.0, and TactiFlex Duo. Bears are less worried about the headline numbers and more focused on execution: electrophysiology growth estimates have been trimmed, Volt only entered full US launch in mid-August, and LAAC market softness looks broader than company-specific. The analyst recommendation factor sits in the 98th percentile of the universe, meaning almost every comparable stock has a weaker consensus. The short score of 28.2 ranks in the 86th percentile for low short pressure, consistent with the lending data. On valuation, the PE has ticked down to 17.2x over the past week, a modest compression that keeps the stock cheaper than the Street's longer-run targets imply.

On the ownership side, BlackRock added 6.9 million shares in the quarter ended September 30 to hold 8.8% of the company, and T. Rowe Price added 3.0 million shares to bring its stake to 1.3%. Those are meaningful additions from two of the largest holders, suggesting institutional conviction held through the pre-earnings period. The Vanguard Group filed an amended 13G in March disclosing a reduction to zero from 10.05%, though Vanguard Capital Management separately holds 7.5% per its April filing. Per ORTEX's EDGAR data, stakes are as-last-disclosed around the 5% threshold, and a holder dropping below 5% may exit without a further filing.

The session's key question now is whether the post-earnings dip toward $102 draws fresh institutional buyers or marks the start of a wider retracement toward the September lows. The next catalyst to watch is management's commentary on electrophysiology growth rates and Volt ramp trajectory, where the bear case centres most heavily.